Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Dec 15;21(24):9558. doi: 10.3390/ijms21249558

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Representative optical coherence tomography (OCT) images of macular thickness. Aflibercept treatment decreased significantly (p < 0.05) foveal macular thickness in non-proliferative diabetic retinopathy (NPDR) and proliferative diabetic retinopathy (PDR) patients, compared to untreated naïve groups. Foveal macular thickness measurement in enrolled subjects beloging to the followig groups: NPDR before (A) and after (B) aflibercept treatment, PDR before (C) and after (D) aflibercept treatment, and OCT evaluation in diabetic patients without DR (E). Mean foveal macular thickness (F) μm ± S.D.; * p < 0.05 vs. diabetic; † p < 0.05 vs. NPDR naïve; ‡ vs. PDR naïve patients.